Epizyme Inc

NASDAQ:EPZM  
12.12
+0.27 (+2.28%)
Other Pre-Announcement

Epizyme Reports Q3 Loss Per Share $0.55

Published: 11/06/2020 11:47 GMT
Epizyme Inc (EPZM) - Epizyme Reports Business Progress and Third Quarter 2020 Financial Results.
Q3 Loss per Share $0.55.
Q3 Revenue $3.6 Million.
Q3 Revenue Estimate $5.4 Million -- Refinitiv Ibes Data (analyst estimates).
Q3 Earnings per Share Estimate $-0.60 -- Refinitiv Ibes Data (analyst estimates).
Epizyme - On-track to Initiate Efficacy Portions of Confirmatory Trials in Es & Fl and Phase 2 Castration-resistant Prostate Cancer Trial in Early 2021.
Updated Guidance for FY Non-GAAP Adjusted Cash Operating Expenses to Between $215 Million to $235 Million.